Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing. Issue 3 (24th January 2023)

• Record Type: Journal Article
• Authors: Noda, Takashi; Ueda, Nobuhiko; Tanaka, Yuji; Ishiguro, Yoko; Matsumoto, Tomoko; Uenishi, Tatsuhiro; Yamaguchi, Hiroko; Shoji, Ayako; Myung, Jae-Eun; Kusano, Kengo
• Is Part Of: Europace. Volume 25:Issue 3(2023)
• Page Start: 1087
• Page End: 1099
• Publication Date: 2023-01-24
• Subjects: Cost-effectiveness -- Atrial fibrillation -- Heart failure -- Pacemaker -- Cardiac resynchronization therapy -- Atrial anti-tachycardia pacing; Arrhythmia -- Treatment -- Periodicals; Cardiac pacing -- Periodicals; Catheter ablation -- Periodicals; Heart -- Physiology -- Periodicals; Electrophysiology -- Periodicals; 617.4120645
• DOI: 10.1093/europace/euad003
• Languages: English
• ISSNs: 1099-5129

Abstract

Abstract: Aims: Reactive atrial-based anti-tachycardia pacing (rATP) in pacemakers (PMs) and cardiac resynchronization therapy defibrillators (CRT-Ds) has been reported to prevent progression of atrial fibrillation, and this reduced progression is expected to decrease the risk of complications such as stroke and heart failure (HF). This study aimed to assess the cost-effectiveness of rATP in PMs and CRT-Ds in the Japanese public health insurance system. Methods and results: We developed a Markov model comprising five states: bradycardia, post-stroke, mild HF, severe HF, and death. For devices with rATP and control devices without rATP, we compared the incremental cost-effectiveness ratio (ICER) from the payer's perspective. Costs were estimated from healthcare resource utilisation data in a Japanese claims database. We evaluated model uncertainty by analysing two scenarios for each device. The ICER was 763 729 JPY/QALY (5616 EUR/QALY) for PMs and 1, 393 280 JPY/QALY (10 245 EUR/QALY) for CRT-Ds. In all scenarios, ICERs were below 5 million JPY/QALY (36 765 EUR/QALY), supporting robustness of the results. Conclusion: According to a willingness to pay threshold of 5 million JPY/QALY, the devices with rATP were cost-effective compared with control devices without rATP, showing that the higher reimbursement price of the functional categories with rATP is justified from a healthcare economic perspective. Graphical Abstract: Graphical Abstract